+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Hodgkin Lymphoma Drug Pipeline Analysis Report 2025

  • PDF Icon

    Drug Pipelines

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102784
Hodgkin lymphoma (HL) is a rare cancer of the lymphatic system, affecting lymph nodes and compromising immune function. Globally, it accounts for 0.4% of newly reported cancer cases and 0.2% of cancer-related deaths. The Hodgkin lymphoma drug pipeline is expanding due to the rising demand for advanced therapies and personalized treatments. There is a growing focus on immunotherapies and targeted drugs to improve patient outcomes. Recent developments include Innovent Biologics' IBI322, a recombinant anti-CD47/PD-L1 bispecific antibody, which showed a 47.8% objective response rate in a Phase I trial for patients resistant to anti-PD-(L)1 therapies. Such emerging treatments promise enhanced efficacy, offering hope for improved survival rates and quality of life.

Report Coverage

The Hodgkin Lymphoma Drug Pipeline Insight Report by the publisher gives comprehensive insights into Hodgkin lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Hodgkin Lymphoma. The Hodgkin lymphoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Hodgkin lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Hodgkin lymphoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Hodgkin lymphoma.

Hodgkin Lymphoma Drug Pipeline Outlook

Hodgkin lymphoma is a type of cancer that affects the lymphatic system, which is a vital part of the body's immune system. It occurs when abnormal lymphocytes, a kind of white blood cell, grow uncontrollably. This can lead to symptoms such as swollen lymph nodes, fatigue, and night sweats. The exact cause of Hodgkin lymphoma is still unclear, but factors like genetic mutations and viral infections, particularly the Epstein-Barr virus (EBV), may increase the risk.

Hodgkin lymphoma treatments typically include chemotherapy, radiation therapy, and immunotherapy. Emerging targeted therapies are proving to be effective options for advanced cases. Early-stage Hodgkin lymphoma often responds well to a combination of chemotherapy and radiation. For patients with relapsed or refractory Hodgkin lymphoma, options such as stem cell transplants and new immunotherapies, including checkpoint inhibitors, show promising outcomes and improved survival rates.

Hodgkin Lymphoma Epidemiology

Globally, Hodgkin lymphoma accounted for 0.4% of newly reported cancer cases and 0.2% of cancer-related deaths in 2020. In the United States, approximately 8,720 new cases and 1,150 deaths are projected for 2025. The United Kingdom reports around 2,200 new cases annually, while India sees approximately 1,000 cases each year. The Hodgkin lymphoma drug pipeline is expanding, focusing on advanced therapies and improved patient outcomes.

Hodgkin Lymphoma - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of Hodgkin lymphoma drug candidates based on several segmentations, including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Monoclonal Antibodies
  • Antibody-Drug Conjugates
  • Small Molecules
  • Cellular Therapies
  • Immunomodulators
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

Hodgkin Lymphoma - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total Hodgkin lymphoma clinical trials.

Hodgkin Lymphoma - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the Hodgkin lymphoma pipeline analysis include monoclonal antibodies, antibody-drug conjugates, small molecules, cellular therapies, immunomodulators, and others. The Hodgkin lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Hodgkin lymphoma.

Hodgkin Lymphoma Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the Hodgkin lymphoma drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Hodgkin lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Hodgkin lymphoma clinical trials:
  • Takeda
  • AstraZeneca
  • Merck Sharp & Dohme LLC
  • Tessa Therapeutics
  • Akeso
  • Guangzhou Gloria Biosciences Co., Ltd.
  • Immune Cell, Inc.
  • Bristol-Myers Squibb
  • Teva Pharmaceuticals
  • Seagen Inc.
  • Incyte Corporation
  • Pfizer

Hodgkin Lymphoma Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Hodgkin lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Hodgkin lymphoma drug candidates.

Drug: Brentuximab Vedotin with Doxorubicin, Vinblastine and Dacarbazine

Brentuximab Vedotin is an antibody-drug conjugate targeting the CD30 antigen on Hodgkin Reed-Sternberg cells. It is a part of a Phase IV study, sponsored by Takeda, which aims to evaluate the safety and efficacy of Brentuximab Vedotin combined with doxorubicin, vinblastine, and dacarbazine (AVD) in adults with untreated Stage 3/4 classical Hodgkin lymphoma.

Drug: Tislelizumab

Tislelizumab is a humanized IgG4 monoclonal antibody developed by BeiGene. It is currently being evaluated in a Phase III study for relapsed or refractory classical Hodgkin lymphoma (cHL). This trial aims to assess its efficacy by measuring Progression-Free Survival (PFS). Tislelizumab blocks PD-1 interactions, with engineered features to enhance antitumor activity and reduce macrophage-related resistance.

Drug: CD30.CAR-T

CD30.CAR-T, sponsored by Tessa Therapeutics, is being evaluated in the Phase II CHARIOT study for patients with relapsed or refractory Hodgkin lymphoma. This therapy uses genetically modified T cells to target CD30+ cancer cells. The study aims to assess safety, tolerability, and efficacy, with primary completion expected by May 2025.

Reasons To Buy This Report

The Hodgkin Lymphoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Hodgkin lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Hodgkin lymphoma collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Hodgkin Lymphoma - Pipeline Insight Report

  • Which companies/institutions are leading the Hodgkin lymphoma drug development?
  • What is the efficacy and safety profile of Hodgkin lymphoma pipeline drugs?
  • Which company is leading the Hodgkin lymphoma pipeline development activities?
  • What is the current Hodgkin lymphoma commercial assessment?
  • What are the opportunities and challenges present in the Hodgkin lymphoma drug pipeline landscape?
  • What is the efficacy and safety profile of Hodgkin lymphoma pipeline drugs?
  • Which company is conducting major trials for Hodgkin lymphoma drugs?
  • Which companies/institutions are involved in Hodgkin lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in Hodgkin lymphoma?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Hodgkin Lymphoma
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Hodgkin Lymphoma
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Hodgkin Lymphoma: Epidemiology Snapshot
5.1 Hodgkin Lymphoma Incidence by Key Markets
5.2 Hodgkin Lymphoma - Patients Seeking Treatment in Key Markets
6 Hodgkin Lymphoma: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Hodgkin Lymphoma: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Hodgkin Lymphoma, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Hodgkin Lymphoma Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Hodgkin Lymphoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Brentuximab Vedotin with Doxorubicin, Vinblastine and Dacarbazine
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: Tislelizumab
10.2.3 Drug: Pembrolizumab with Brentuximab Vedotin
10.2.4 Other Drugs
11 Hodgkin Lymphoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: CD30.CAR-T
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: AZD3470
11.2.3 Other Drugs
12 Hodgkin Lymphoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Biological: ICAR30 T cells
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Hodgkin Lymphoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Hodgkin Lymphoma, Key Drug Pipeline Companies
14.1 Takeda
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 AstraZeneca
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Merck Sharp & Dohme LLC
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Tessa Therapeutics
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Akeso
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Guangzhou Gloria Biosciences Co., Ltd.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Immune Cell, Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Bristol-Myers Squibb
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 Teva Pharmaceuticals
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
14.10 Seagen Inc.
14.10.1 Company Snapshot
14.10.2 Pipeline Product Portfolio
14.10.3 Financial Analysis
14.10.4 Recent News and Developments
14.11 Incyte Corporation
14.11.1 Company Snapshot
14.11.2 Pipeline Product Portfolio
14.11.3 Financial Analysis
14.11.4 Recent News and Developments
14.12 Pfizer
14.12.1 Company Snapshot
14.12.2 Pipeline Product Portfolio
14.12.3 Financial Analysis
14.12.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products